Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00055. Epub 2018 Jun 5. No abstract available.

2.

Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy.

Kim SH, Roszik J, Grimm EA, Ekmekcioglu S.

Front Oncol. 2018 Mar 16;8:67. doi: 10.3389/fonc.2018.00067. eCollection 2018. Review.

3.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

4.

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J.

Front Immunol. 2017 Jun 16;8:689. doi: 10.3389/fimmu.2017.00689. eCollection 2017.

5.

A tool for discovering drug sensitivity and gene expression associations in cancer cells.

Qin Y, Conley AP, Grimm EA, Roszik J.

PLoS One. 2017 Apr 28;12(4):e0176763. doi: 10.1371/journal.pone.0176763. eCollection 2017.

6.

Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.

Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW.

Neoplasia. 2017 Mar;19(3):237-249. doi: 10.1016/j.neo.2016.07.009.

7.

Targeting iNOS to increase efficacy of immunotherapies.

Ekmekcioglu S, Grimm EA, Roszik J.

Hum Vaccin Immunother. 2017 May 4;13(5):1105-1108. doi: 10.1080/21645515.2016.1276682. Epub 2017 Jan 25.

8.

Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.

Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C.

Melanoma Res. 2017 Apr;27(2):126-133. doi: 10.1097/CMR.0000000000000329.

PMID:
28118269
9.

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.

Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J.

Sci Rep. 2016 Oct 20;6:35848. doi: 10.1038/srep35848.

11.

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA.

Mol Cancer Ther. 2016 Oct;15(10):2442-2454. Epub 2016 Jul 25.

12.

Uveal melanoma: From diagnosis to treatment and the science in between.

Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP.

Cancer. 2016 Aug 1;122(15):2299-312. doi: 10.1002/cncr.29727. Epub 2016 Mar 15. Review.

13.

Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.

Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA.

Medicine (Baltimore). 2016 Mar;95(11):e3073. doi: 10.1097/MD.0000000000003073.

14.

Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.

Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2016 May;29(3):297-308. doi: 10.1111/pcmr.12455. Epub 2016 Mar 15.

15.

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.

Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL Jr, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA.

Clin Cancer Res. 2016 Jun 15;22(12):3016-24. doi: 10.1158/1078-0432.CCR-15-2226. Epub 2016 Jan 18.

16.

IL-10: Expanding the Immune Oncology Horizon.

Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB.

Receptors Clin Investig. 2015;2(4). pii: 1041. Epub 2015 Nov 4.

17.

Dual Roles of RNF2 in Melanoma Progression.

Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L.

Cancer Discov. 2015 Dec;5(12):1314-27. doi: 10.1158/2159-8290.CD-15-0493. Epub 2015 Oct 8.

18.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2901. doi: 10.1038/jid.2015.259. Epub 2015 Jul 16. No abstract available.

19.

Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.

Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA.

J Invest Dermatol. 2015 Nov;135(11):2775-2784. doi: 10.1038/jid.2015.204. Epub 2015 Jun 3. Erratum in: J Invest Dermatol. 2015 Nov;135(11):2901.

20.

Inflammatory IL-1β-driven JNK activation in stage III melanoma.

Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2015 Mar;28(2):236-9. doi: 10.1111/pcmr.12348. Epub 2015 Jan 12. No abstract available.

PMID:
25546243
21.

4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.

Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q.

Melanoma Res. 2016 Apr;26(2):181-7. doi: 10.1097/CMR.0000000000000106.

22.

Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.

Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V.

Transl Oncol. 2014 Aug;7(4):484-92. doi: 10.1016/j.tranon.2014.05.008. Epub 2014 Jun 23.

23.

Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.

Chattopadhyay C, Grimm EA, Woodman SE.

PLoS One. 2014 Feb 13;9(2):e83957. doi: 10.1371/journal.pone.0083957. eCollection 2014.

24.

Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.

Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG.

Cancer Res. 2014 Feb 15;74(4):1067-78. doi: 10.1158/0008-5472.CAN-13-0588. Epub 2014 Jan 7.

25.

Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Grimm EA, Sikora AG, Ekmekcioglu S.

Clin Cancer Res. 2013 Oct 15;19(20):5557-63. doi: 10.1158/1078-0432.CCR-12-1554. Epub 2013 Jul 18. Review.

26.

Polymorphisms of nucleotide excision repair genes predict melanoma survival.

Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q.

J Invest Dermatol. 2013 Jul;133(7):1813-21. doi: 10.1038/jid.2012.498. Epub 2013 Feb 14.

27.

Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population.

Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q.

Pigment Cell Melanoma Res. 2013 May;26(3):422-5. doi: 10.1111/pcmr.12070. Epub 2013 Feb 19. No abstract available.

28.

Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.

Qin Y, Deng W, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2013 Jan;26(1):97-112. doi: 10.1111/pcmr.12031. Epub 2012 Nov 6.

29.

Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes.

Shirley SH, Grimm EA, Kusewitt DF.

J Skin Cancer. 2012;2012:410925. doi: 10.1155/2012/410925. Epub 2012 Jun 13.

30.

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA.

PLoS One. 2012;7(4):e34833. doi: 10.1371/journal.pone.0034833. Epub 2012 Apr 25.

31.

Slug expression during melanoma progression.

Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF.

Am J Pathol. 2012 Jun;180(6):2479-89. doi: 10.1016/j.ajpath.2012.02.014. Epub 2012 Apr 13.

32.

The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival.

Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB.

Oncotarget. 2012 Mar;3(3):336-44.

33.

Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.

Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE.

Melanoma Res. 2012 Apr;22(2):169-75. doi: 10.1097/CMR.0b013e32834fc46b.

34.

IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA.

Melanoma Res. 2012 Feb;22(1):19-29. doi: 10.1097/CMR.0b013e32834d2506.

35.

Association of activated c-Met with NRAS-mutated human melanomas.

Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA.

Int J Cancer. 2012 Jul 15;131(2):E56-65. doi: 10.1002/ijc.26487. Epub 2012 Jan 11.

36.

Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.

Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA.

Mol Cancer Res. 2011 Nov;9(11):1537-50. doi: 10.1158/1541-7786.MCR-11-0279. Epub 2011 Sep 27.

37.
38.

Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH; GenoMEL Investigators, MacGregor S, Hayward NK, Martin NG, Duffy DL; Q-Mega Investigators, Mann GJ, Cust A, Hopper J; AMFS Investigators, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q.

Hum Mol Genet. 2011 Dec 15;20(24):5012-23. doi: 10.1093/hmg/ddr415. Epub 2011 Sep 17.

39.

Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells.

Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A Jr, Newman RA, Grimm EA.

Nutr Cancer. 2011;63(6):940-9. doi: 10.1080/01635581.2011.586488. Epub 2011 Jul 11.

PMID:
21745040
40.

Tumor suppressor gene-based nanotherapy: from test tube to the clinic.

Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R.

J Drug Deliv. 2011;2011:465845. doi: 10.1155/2011/465845. Epub 2011 Jan 24.

41.

Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA.

Clin Cancer Res. 2011 Jan 15;17(2):229-35. doi: 10.1158/1078-0432.CCR-10-2276. Epub 2010 Oct 25. Erratum in: Clin Cancer Res. 2011 Mar 15;17(6):1641.

42.

Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.

Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q.

Eur J Cancer. 2011 Jan;47(1):107-15. doi: 10.1016/j.ejca.2010.06.129. Epub 2010 Jul 23.

43.

IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.

Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA.

Exp Dermatol. 2010 Aug;19(8):714-22. doi: 10.1111/j.1600-0625.2010.01077.x.

44.

IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.

Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA.

Melanoma Res. 2011 Feb;21(1):44-56. doi: 10.1097/CMR.0b013e3283382155.

45.

Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.

Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW.

Clin Cancer Res. 2010 Mar 15;16(6):1834-44. doi: 10.1158/1078-0432.CCR-09-3123. Epub 2010 Mar 9.

46.

Promotion of melanoma growth by the metabolic hormone leptin.

Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA.

Oncol Rep. 2010 Apr;23(4):901-7.

47.

Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma.

Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA.

J Urol. 2009 Mar;181(3):1028-34; discussion 1034. doi: 10.1016/j.juro.2008.11.013. Epub 2009 Jan 16.

48.

Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.

Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S.

Mol Cancer Ther. 2008 Dec;7(12):3842-51. doi: 10.1158/1535-7163.MCT-08-0516. Epub 2008 Dec 3.

49.

Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

Greene VR, Johnson MM, Grimm EA, Ellerhorst JA.

J Invest Dermatol. 2009 Jun;129(6):1483-8. doi: 10.1038/jid.2008.374.

50.

A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.

Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB.

Clin Cancer Res. 2008 Sep 15;14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377.

Supplemental Content

Loading ...
Support Center